{"id":"bezuclastinib-in-combination-with-sunitinib","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Hypertension"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Nausea"},{"rate":"5-20%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL597365","moleculeType":"Small molecule","molecularWeight":"398.48"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bezuclastinib works by inhibiting the activity of KIT and PDGFRα, which are proteins that help cancer cells grow and divide. By blocking these proteins, bezuclastinib can slow or stop the growth of cancer cells. When used in combination with sunitinib, bezuclastinib may help to improve treatment outcomes for patients with GIST.","oneSentence":"Bezuclastinib is a tyrosine kinase inhibitor that targets KIT and PDGFRα, and in combination with sunitinib, it is used to treat gastrointestinal stromal tumors (GIST).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:58:04.629Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastrointestinal stromal tumors (GIST)"}]},"trialDetails":[{"nctId":"NCT05489237","phase":"PHASE1","title":"First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors","status":"RECRUITING","sponsor":"IDRx Inc. - A GSK Company","startDate":"2022-08-03","conditions":"Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease","enrollment":278},{"nctId":"NCT06208748","phase":"PHASE2","title":"SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sarcoma Alliance for Research through Collaboration","startDate":"2024-08-01","conditions":"Gastrointestinal Stromal Tumors, GIST","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Bezuclastinib in combination with sunitinib","genericName":"Bezuclastinib in combination with sunitinib","companyName":"Sarcoma Alliance for Research through Collaboration","companyId":"sarcoma-alliance-for-research-through-collaboration","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bezuclastinib is a tyrosine kinase inhibitor that targets KIT and PDGFRα, and in combination with sunitinib, it is used to treat gastrointestinal stromal tumors (GIST). Used for Gastrointestinal stromal tumors (GIST).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}